Macquarie Group Ltd. bought a new stake in shares of Chemours Company (The) (NYSE:CC) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 57,300 shares of the specialty chemicals company’s stock, valued at approximately $2,173,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. FMR LLC boosted its position in Chemours Company (The) by 6.1% during the 2nd quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock valued at $600,289,000 after acquiring an additional 905,038 shares in the last quarter. State Street Corp boosted its position in Chemours Company (The) by 35.1% during the 1st quarter. State Street Corp now owns 5,791,792 shares of the specialty chemicals company’s stock valued at $222,987,000 after acquiring an additional 1,504,657 shares in the last quarter. Renaissance Technologies LLC boosted its position in Chemours Company (The) by 10.3% during the 2nd quarter. Renaissance Technologies LLC now owns 3,342,200 shares of the specialty chemicals company’s stock valued at $126,736,000 after acquiring an additional 310,800 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Chemours Company (The) by 10.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,966,582 shares of the specialty chemicals company’s stock valued at $74,573,000 after acquiring an additional 186,228 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Chemours Company (The) by 126.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company’s stock valued at $67,843,000 after acquiring an additional 999,380 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

In related news, VP Amy Trojanowski sold 2,500 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.03, for a total transaction of $115,075.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David C. Shelton sold 5,908 shares of the business’s stock in a transaction on Friday, October 13th. The stock was sold at an average price of $56.01, for a total transaction of $330,907.08. Following the transaction, the senior vice president now owns 47,356 shares of the company’s stock, valued at approximately $2,652,409.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 77,142 shares of company stock valued at $3,953,265. Insiders own 1.14% of the company’s stock.

Several analysts have issued reports on CC shares. BidaskClub cut Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Zacks Investment Research cut Chemours Company (The) from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Citigroup Inc. raised Chemours Company (The) from a “neutral” rating to a “buy” rating and increased their target price for the company from $43.00 to $45.00 in a research report on Wednesday, July 5th. Jefferies Group LLC increased their target price on Chemours Company (The) to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Argus reiterated a “buy” rating and set a $55.00 price objective (up previously from $50.00) on shares of Chemours Company (The) in a report on Thursday, August 10th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Chemours Company (The) presently has an average rating of “Buy” and an average price target of $52.75.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/23/macquarie-group-ltd-takes-2-17-million-position-in-chemours-company-the-cc.html.

Shares of Chemours Company (NYSE:CC) opened at 55.89 on Monday. Chemours Company has a one year low of $15.90 and a one year high of $57.68. The stock’s 50 day moving average price is $52.35 and its 200 day moving average price is $44.61. The stock has a market cap of $10.33 billion, a price-to-earnings ratio of 36.58 and a beta of 3.59.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.02. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.27 earnings per share. Analysts forecast that Chemours Company will post $3.57 earnings per share for the current year.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.